Medical device and MedTech insights, news, tips and more

ReadCoor, Inc. Unveils True Spatial Sequencing Platform to Drive Groundbreaking Insights into Immuno-oncology, Neuroscience, and Infectious Disease 

February 24, 2020


ReadCoor, Inc., a company leading true multi-omic spatial sequencing, today unveils its first product line, including multi-omic spatial sequencing assays and the RC2 instrument. The platform is powered by ReadCoor’s proprietary FISSEQ (Fluorescent in situ Sequencing) technology, which combines the massive multiplexity of next-generation sequencing (NGS) and high-resolution tissue imaging. The fully integrated platform is now available for use by researchers through ReadCoor’s Select Release Program (SRP), focusing on initial applications in immuno-oncology, neuroscience, and infectious disease, as well as a custom offering. ReadCoor has increased its Series B investment round to $30 million to accelerate commercial efforts.


The new platform simultaneously detects tens to thousands of RNA and DNA sequences, proteins, and therapeutic molecules at nanoscale 3D resolution in every cell within an intact tissue sample. The key products launched today are:

  • Automated, turn-key spatial sequencing instrument called RC2 that captures sub-cellular complexity at nanoscale resolution across entire tissue sections.
  • Application Kits containing all components necessary to prepare tissue samples for spatial sequencing on the RC2 in a single sample processing workflow.
    • Sample slides provide optimized surfaces compatible with standard sectioning workflows for FFPE, fixed frozen, or fresh frozen tissues and feature markings to guide tissue placement.
  • Instrument Kits contain all necessary bulk and sequencing reagents to collect spatial sequencing information from up to four tissue samples per run.
  • Analysis and Visualization Cloudware that fully integrates data management and analysis. Users can manage and analyze sub-cellular molecular information with visualization tools that display molecular and morphological volumes, display locations for all multi-omic targets in 3D, select regions of interest, and employ spatial statistical methods for unbiased discovery.

“We firmly believe our true multi-omic sequencing technology will have a dramatic impact on medicine and healthcare, and this motivates us to provide researchers products that offer unprecedented and meaningful insights into human biology,” said Richard Terry, Chief Executive Officer, Chief Technical Officer, and Founder of ReadCoor. “Our Select Release Program serves as the foundation for researchers to develop new therapeutics and treatments to ultimately improve patient care.”

Users within the SRP can use ReadCoor’s initial applications to support their specific research interests. The applications offer the following capabilities:

  • Immuno-oncology
    ReadCoor’s immuno-oncology application unifies disparate histological and molecular assays, eliminating the need to allocate precious tumor samples between anatomical and molecular pathology methods. This approach could increase the efficacy of IO treatments for meaningful clinical insights in immuno-oncology, pathology, and drug discovery.
  • Neuroscience
    Comprehensive cell function and phenotyping to atlas the brain using the RC2 platform will have enormous benefits to both basic neuroscience research and biomedical applications such as understanding and treating traumatic brain injury and neurodegenerative diseases.
  • Infectious Disease
    ReadCoor’s initial infectious disease application is designed to advance understanding of HIV biology. This approach has the potential to provide insights into many aspects of HIV’s lifecycle and ultimately inform better treatment options towards eradicating this disease.

See Full Press Release: ReadCoor, Inc. Unveils True Spatial Sequencing Platform to Drive Groundbreaking Insights into Immuno-oncology, Neuroscience, and Infectious Disease | Business Wire

Written by: ReadCoor, Inc.

Legacy MedSearch has more than 30 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 10 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?

Contact us to discuss partnering with Legacy MedSearch on your position.

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.